Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) insider Martin Javier San sold 19,500 shares of Arrowhead Pharmaceuticals stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $29.99, for a total value of $584,805.00. Following the completion of the transaction, the insider now owns 91,500 shares in the company, valued at approximately $2,744,085. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Arrowhead Pharmaceuticals Trading Down 0.5 %
Shares of NASDAQ:ARWR opened at $29.40 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $26.81 and a 12-month high of $74.77. The company has a market capitalization of $3.11 billion, a PE ratio of -19.86 and a beta of 1.42. The business has a 50 day moving average of $32.85 and a two-hundred day moving average of $36.24. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.16.
Analysts Set New Price Targets
ARWR has been the topic of a number of research analyst reports. Piper Sandler dropped their price target on Arrowhead Pharmaceuticals from $72.00 to $64.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 9th. StockNews.com initiated coverage on Arrowhead Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. The Goldman Sachs Group boosted their price target on Arrowhead Pharmaceuticals from $58.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, August 8th. Morgan Stanley initiated coverage on Arrowhead Pharmaceuticals in a research note on Friday, September 9th. They set an “equal weight” rating and a $41.00 price target on the stock. Finally, Chardan Capital boosted their price target on Arrowhead Pharmaceuticals from $80.00 to $82.00 in a research note on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $65.00.
Institutional Inflows and Outflows
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma.
- Get a free copy of the StockNews.com research report on Arrowhead Pharmaceuticals (ARWR)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.